VCN-01
Head and Neck Squamous Cell Carcinoma (HNSCC)
Key Facts
About Theriva Biologics
Theriva Biologics is advancing a differentiated oncolytic virus platform engineered for systemic intravenous delivery, a key limitation of earlier therapies. Its lead candidate, VCN-01, has demonstrated promising clinical activity in metastatic pancreatic ductal adenocarcinoma (PDAC) and is positioned for a pivotal Phase 3 trial following a positive End-of-Phase 2 FDA meeting. The company's strategy focuses on leveraging its stroma-degrading and Albumin Shield™ technologies to treat difficult-to-treat solid tumors, both as monotherapy and in combination with chemotherapy and immunotherapy.
View full company profileAbout Theriva Biologics
Theriva Biologics is advancing a differentiated oncolytic virus platform engineered for systemic intravenous delivery, a key limitation of earlier therapies. Its lead candidate, VCN-01, has demonstrated promising clinical activity in metastatic pancreatic ductal adenocarcinoma (PDAC) and is positioned for a pivotal Phase 3 trial following a positive End-of-Phase 2 FDA meeting. The company's strategy focuses on leveraging its stroma-degrading and Albumin Shield™ technologies to treat difficult-to-treat solid tumors, both as monotherapy and in combination with chemotherapy and immunotherapy.
View full company profileTherapeutic Areas
Other Head and Neck Squamous Cell Carcinoma (HNSCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Membrex™ | Metaclipse Therapeutics | Phase 1 |
| CXR101 | CorriXR Therapeutics | Pre-clinical |